important factor, with 31% of transplant recipients stating that ISTrelated expenses have an adverse impact on their lives 6 and 9% reporting insufficient money to buy their medications. 7 In the United States, purchasing IST requires patients to navigate health plans and insurance systems whose coverage policies were designed to minimize costs.
Approximately 30 000 organ transplants were performed in the United States in 2015, and more than 440 000 have been performed since 2000. 8 Table 1 summarizes the insurance carried by US transplant recipients at the time of transplant. 9 Among kidney recipients, Medicare Part B covers IST only when 3 conditions are present:
(1) Medicare Part A was in place or retroactive prior to the transplant date, (2) the transplant occurred in a Medicare-approved facility, and (3) the patient was enrolled in Medicare Part B at the time the IST claim was processed. 10 These criteria are not organ-specific; they apply across all transplanted organs. 
| MATERIAL S AND ME THODS

| Data sources
This study used data from the Scientific Registry of Transplant After institutional review board and HRSA approvals, SHS records were linked with SRTR records for transplant recipients. A deterministic de-identification strategy was applied, wherein patient identifiers (last name, first name, date of birth, sex, and ZIP code of residence)
Recipients (SRTR
were transformed before delivery to the Saint Louis University researchers with Health Information Portability and Accountability Act (HIPAA) and HITECH-certified encryption technology from SHS. The patient de-identification software employs multiple encryption algorithms in succession to guarantee that the resulting "token" containing encrypted patient identifiers can never be decrypted. However, the algorithm yields the same results for a given set of data elements, such that linkages by unique anonymous tokens are possible. Because of the large sample size, the anonymity of the patients studied, and the nonintrusive nature of the research, a waiver of informed consent was granted by the DHHS (45 CFR 46.116). Analyses were performed using HIPAA-compliant limited datasets. 
| Study sample
| RE SULTS
The proportion of transplant recipients vulnerable to immunosuppression coverage denial by Medicare Part D plans ranged from 0% to 66.5%, depending on the organ transplanted. 
| Kidney
All immunosuppressants are either FDA-approved for use in kidney transplantation or mentioned in the CMS-approved compendia as appropriate for use in kidney transplantation. As a result, all kidney transplant recipients who rely on Medicare Part D for IST coverage will experience approved and paid claims.
| Lung
No immunosuppressant is FDA-approved for use in lung transplan- caution, approximately 7% of liver transplant recipients are prescribed sirolimus, often in cases of malignancy or calcineurin inhibitor toxicity. In fact, sirolimus may offer a survival benefit for liver transplant recipients with hepatocellular carcinoma recurrence.
| Liver
TA B L E 3 Number of transplant recipients on medications vulnerable to claim denials under the current Medicare Part D drug benefit rules
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The alternate medication, everolimus, does not have the same black box warning but is marketed as a tablet that should not be cut or crushed, limiting substitution for sirolimus.
| Heart
Tacrolimus, cyclosporine, and mycophenolate mofetil are FDAapproved for use in heart transplantation. The CMS-approved compendia expand this by mentioning leflunomide as appropriate for use in organ transplantation. Heart transplant recipients requiring mycophenolate sodium, azathioprine, sirolimus, or everolimus are vulnerable to claim denials. At 1, 2, and 3 years posttransplantation, 18.5%, 22.2%, and 24.6% of heart transplant recipients are prescribed at least 1 medication that is vulnerable to a denied claim.
Everolimus carries a black box warning stating that use in heart
transplantation is not recommended due to increased mortality in a heart transplant clinical trial. 21 This reported risk resulted in minimal use, with only 1% of heart transplant recipients using everolimus throughout the study period. Notably, however, guidelines for management of heart transplant recipients recommend substituting a mammalian target of rapamycin (mTOR) inhibitor for the antimetabolite upon identification of cardiac allograft vasculopathy (class IIa, level of evidence B). 24 Despite this unique recommendation, neither mTOR inhibitor is FDA-approved or mentioned as appropriate for use in heart transplantation by the CMS-approved compendia.
| Pancreas
As in lung and intestine transplantation, no immunosuppressants are FDA-approved for use in pancreas transplantation. However, the CMS-approved compendia broadly expand drug access by endorsing mycophenolate mofetil and azathioprine in addition to tacrolimus, cyclosporine, and leflunomide for use in pancreas transplantation.
IST for which a pancreas-alone recipient is vulnerable to denied claims include mycophenolate sodium, sirolimus, and everolimus. At 1, 2, and 3 years posttransplantation, 36.8%, 32.9%, and 30.4% of pancreas transplant recipients are prescribed at least 1 medication that is vulnerable to a denied claim.
| Intestine
No immunosuppressants are FDA-approved for use in intestine transplantation. Only tacrolimus and leflunomide are mentioned in the CMS-approved compendia as appropriate for off-label use.
All other medications are vulnerable to claim denials. At 1, 2, and 
| Estimated cost of current off-label and offcompendia immunosuppressant use
| D ISCUSS I ON
Using a novel database including actual pharmaceutical fill records, 
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